Precise epidermal delivery

Best-in-Class   Laser-Assisted   Epidermal Drug Delivery   EPIDRUG™ & EPIMMUN™

Company profile Location Ruggell, Liechtenstein Foundation 2005 Dec. Key assets - proprietary technology in epidermal delivery of immunogens and drugs - portfolio of granted patents and patent applications - EPIMMUN™: promising pre- clinical results for delivery of variety of immunogens - EPIDRUG™: clinical proof of concept for several drugs Investors Private investors, VC company

Pantec’s device – P.L.E.A.S.E. Professional P.L.E.A.S.E. = Precise Laser EpidermAl System The only existing Ablative Laser Class 1 Full delegation - to be used by non-doctoral staff No safety precautions required User-friendly interface for easy programming Small and mobile for easy use Precise and painless delivery Patent protected Medical CE marked

Applications– EPIDRUG™ & EPIMMUN™ EPIDRUG™ and EPIMMUN™ allows for optimal, dose-controlled delivery of various drug and immunogen substances into targeted skin layers offering an optimal safety profile and in case of EPIMMUN™ inducing an active immune-response and triggering a laser adjuvant effect. 5

EPIMMUN™ and EPIDRUG™ Process Precise and reproducible formation of micropores in desired skin layer Topical administration of substance Efficient delivery of substance through micropores and uptake relevant immune cells or receptors

Laser-assisted generation of micropores – the basis of the P. L. E. A Laser-assisted generation of micropores – the basis of the P.L.E.A.S.E. platform We love micro-Pores!

Precise Laser EpidermAl SystEm EPIMMUN™ and EPIDRUG ™ allow for precise, dose-controlled delivery of various substances into targeted skin layers, offering an optimal safety profile. EPIMMUNTM EPIDRUG™ Precise epidermal delivery + Immune stimulant effect; laser adjuvant effect Precise epidermal delivery P.L.E.A.S.E. Precise Laser EpidermAl SystEm

Precise micropore depth - delivery to target skin layers 9

Key advantages of EPIMMUN™ and EPIDRUG™ Easy to use, needle-less, painless, well-tolerated Reproducible formation of micropores Precise depth Desired skin layers Induction of strong immune response (EPIMMUN™ only) Precise immunogen delivery to target immune cells Immune-stimulant effect 200 mm 60 mm

Market and Fields of Application Oncology active Immunotherapy WW sales in 2014 of $ 41 billion1 Cancer immunotherapy is „ breakthrough treatment of the year 2013“ Checkpoint inhibitors and their combination with cancer active immunotherapies will substantially contribute to expected growth of the market High medical need for effective immunogen delivery to target immune cells Preventive and therapeutic vaccines WW sales of $ 33 billion in 2014 expected to grow to $56 billion in 20192 Needle-less delivery systems are highly needed, particularly in the developing world Allergy immunotherapy WW sales of $ 1,1 billion in 20143 Highly underserved market – only 2% of allergic patents are currently treated because of cumbersome treatment schedules (>50 injections) over long period (>3 years) Autoimmune disease drugs WW sales expected at $ 61 billion in 20174 Unmet medical need for local targeted delivery (reduce side effects of systemic drug administration) Combined market potential > $100 billion 1 Global & USA Cancer Immunotherapy Market Analysis to 2020 2 Markets and Markets 2015, „Vaccine market by technology – Forecast to 2019 3 ALK, Annual Report 2014 4 GBI Research, Autoimmune Disorders Therapeutics Market to 2017

Business Model Formation of partnerships with biotech and pharmaceutical companies for commercialization of combination products using EPIDRUG™ or EPIMMUNTM together with their proprietary drug or vaccine formulations To achieve this objective, Pantec will generate broad database of preclinical and clinical data with EPIDRUG™ and EPIMMUNTM in wide variety of indications in collaboration with (existing and newly formed) research partnerships with leading academic institutions and biotech companies will use this database to convince pharma companies to combine their substances with EPIDRUG™ and EPIMMUNTM will enter into licensing agreements with pharma partners in return for upfront and milestone fees as well as royalties

Revenue Generation Sales of devices and consumables Licensing revenues Short Term: Laser devices (and consumables) on rental or purchase basis for research partners Mid Term: Sales of laser devices and consumables to clinical trial centers and pharma companies conducting studies with partnered products Cumulative sales revenues of ~ € 1,7 million projected until 2018 (2015: ~ € 500.000) Long Term: After launch of partnered product(s) (first launch expected in 2019) substantial increase in sales of laser devices and consumables to end users (physicians) Licensing revenues Upfront, Milestone and Royalty payments from pharma partners Pantec has already signed three such licensing agreements with pharma and biotech companies

Financials – Financing Round Financing Volume: € 4 Million Funding reach: end 2018 Use of Proceeds: Business development and marketing/sales activities to leading scientific research institutions and biotech companies Support of research institutions to generate strong EPIDRUG™/EPIMMUNTM preclinical/clinical data base Business development for further pharma partnerships Engineering and design of next generation laser device Maintenance and Extension of IP portfolio Key milestones Successful clinical study as part of existing EPIDRUG™ Pharma collaborations mid of 2016 First clinical data with EPIMMUNTM by end of 2016 Pharma partnership for EPIMMUNTM in 2017 Operational profitability in 2019 Exit potential – As a profitable Medtech company with significant growth potential, Pantec would be an attractive M&A partner for Medtech and pharma companies would be an attractive investment case to go public

Management Team Reinhard Braun, Co-Founder, President and CEO Founder, President and CEO of Pantec Engineering AG Engineering Degree in Electronics Christof Böhler, PhD, Co-Founder, Exec. Director Business Development CEO at Pantec Biosolutions from 2006 to 2014 PhD in Chemistry and executive degree in International Management Elmira Lechat, MD, MBA, Medical Director Clinical Services Supervisor/Medical Scientific Expert at Medtronic Assistant at European Respiratory Society Martin Steiner, PhD, MBA, Business Development EPIMMUNTM Consultant to biotechnology companies Founder and CEO of two biotechnology companies PhD in Microbiology and Genetics and MBA Tobias Bächle, Sales Director Senior Regional Sales Manager at Bio Separations GmbH and Macherey-Nagel AG Engineering Degree in Chemistry

Key achievements to date Laser platform developed at high quality standards P.L.E.A.S.E. laser platform developed, manufactured and medical CE-marked Established quality management system, ISO certification Pharma collaborations in place Collaborations with Takeda, Ratiopharm and Oncosynergy (Biotech) actively running First-mover and pioneer in epidermal drug delivery for dermatology and immunotherapy Strong IP position established Portfolio of patents granted or filed to protect laser device, as well as EPIDRUG™ and EPIMMUN™ Profound technological and application know-how Promising preclinical data EPIMMUN™ concept successfully demonstrated in several animal studies Activation of relevant immune cells and induction of strong immune response by EPIMMUNTM Clinical experience Completed clinical studies EPIDRUG™ prove safe, well-tolerated and reproducible laser microporation Ongoing clinical project with Takeda Pharmaceuticals Strong scientific network Collaborations with leading research groups in different fields of immunotherapy established Several devices sold or rented to academic institutions and biotech companies

Investment Considerations Proprietary, widely-applicable platform technology EPIDRUG™ and EPIMMUN™ are pre-clinically and clinically tested with different substances for several different indications Focus on rapidly –growing immunotherapy market Pantec is a leading first-mover and pioneer with proprietary technology and know-how Pantec has extensive network of leading scientific research groups and key opinion leaders Immunotherapy and vaccine market currently more than 75 billion Management team with extensive know-how and experience Multi-year experience in various senior management roles with biotechnology, pharmaceutical and medical technology companies Financially attractive, low-risk investment Low technology risk – clinical experience shows excellent safety profile Existing partnerships with pharma and biotechnology company Platform applicable to a wide range of indications with large market potential Attractive Exit potential Early break even (i.e. before partnered products enter market) Attractive M&A partner or IPO candidate